AstraZeneca Pharma India, a subsidiary company of AstraZeneca Pharmaceuticals AB, Sweden, has decided to delist its scrip from Bombay Stock Exchange, National Stock Exchange and Bangalore Stock Exchange in accordance with Regulation 8 (1) (a) of the delisting regulations. The board of directors approved the proposal today.

With this announcement, AstraZeneca scrip moved up sharply by Rs 201 at its new 52 weeks peak level at Rs 1207 on BSE. The market capitalization worked out to Rs 3,017 crore. At present foreign promoters are holding 90 per cent of its equity capital of Rs 5 crore.

AstraZeneca has posted net sales of Rs 385 crore during the year ended December 2009 and earned a net profit of Rs 57.62 crore with EPS of Rs 23.05. The company has changed its accounting year from January-December to April-March for the current year.